共 50 条
- [1] Phase 1 clinical trial using mbIL21 ex vivo-expanded donor-derived NK cells after haploidentical transplantationBLOOD, 2017, 130 (16) : 1857 - 1868Ciurea, Stefan O.Schafer, Jolie R.Bassett, RolandDenman, Cecele J.Cao, KaiWillis, DanaRondon, GabrielaChen, JulianneSoebbing, DorisKaur, IndreshpalGulbis, AlisonAhmed, SairahRezvani, KatayounShpall, Elizabeth J.Lee, Dean A.Champlin, Richard E.
- [2] DONOR-DERIVED CAR-T CELLS FOR THE TREATMENT OF RELAPSED ACUTE B-LYMPHOBLASTIC LEUKEMIA AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATIONBONE MARROW TRANSPLANTATION, 2024, 59 : 47 - 48Deng, LeiYu, XiaolinSong, XiaochengGuan, RuiShao, YanLi, WenjunZhou, Fang
- [3] Infusion of Ex-Vivo expanded donor T cells to improve graft-derived T-cell reconstitution after allogeneic hematopoietic stem cell transplantationBLOOD, 2007, 110 (11) : 957A - 958AMontcuquet, NicolasPerruche, SylvainShipman, BenjaminMarandin-Decock, AlietteBonnefoy, FrancisSaas, PhilippeRobinet, EricTiberghien, Pierre
- [4] Phase I Trial of Ex Vivo Expanded Donor Gamma Delta T Cell Immunotherapy to Prevent Acute Myeloid Leukemia Relapse after Allogeneic TransplantationTRANSPLANTATION AND CELLULAR THERAPY, 2025, 31 (02):Bejanyan, NelliElmariah, HanyKim, JongphilCox, CherylLowden, MelissaSong, XiaofeiLiu, HienYu, BinReid, KaylaYoder, SeanCubitt, ChristopherFaramand, RawanMirza, Abu-SayeefKhimani, FarhadPerez, Lia ElenaOchoa-Bayona, Jose-LeonelBoucher, JustinGuevara, Jose AlejandroSallman, David A.Lancet, Jeffrey E.Pidala, JosephKaryampudi, KumarLocke, Frederick L.Anasetti, ClaudioDavila, Marco L.
- [5] Role of Donor-Derived CD19.CAR-T Cells in Treating Patients That Relapsed after Allogeneic Hematopoietic Stem Cell TransplantationBLOOD, 2019, 134Zhang, ChengGao, LeiLiu, YaoGao, LiKong, Pei-YanLiu, JunHuang, RuihaoMa, Ying-YingZeng, DefuXiong, Qing-HuiMei, Wei-LingLiu, JiaJiang, Peng-FeiYe, XunHan, De-PingCao, WeiZhang, Xi
- [6] INTERIM ANALYSIS OF PHASE I/II TRIAL IN HIGH-RISK PEDIATRIC PATIENTS POST ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT (HSCT) TREATED WITH EX VIVO EXPANDED DONOR-DERIVED ADENOVIRUS-SPECIFIC T CELLSHAEMATOLOGICA, 2015, 100 : 288 - 288Ip, W.Stansfield, A.Skulte, A.Gilmour, K.Brocklesby, M.Ahsan, G.Amrolia, P.Veys, P.Gaspar, B.Qasim, W.
- [7] An analysis of a first-in-human study of NEXI-001 donor-derived antigen-specific CD8+T-cell treatment of relapsed AML after allogeneic hematopoietic cell transplantation (HCT)JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)Al Malki, Monzr M.Vasu, SumithiraModi, DipenkumarAfonso-Smith, Suzanne D.Kim, SojungLu, EmilyMarcucci, GuidoOelke, MathiasKnight, Robert D.Varela, Juan Carlos
- [9] Initial Characterization of Nexi-001, a Donor-Derived T-Cell Product, for the Treatment AML Patients That Have Relapsed after Allogeneic Hematopoietic Stem Cell TransplantBLOOD, 2022, 140 : 4521 - 4521Varela, Juan CarlosKim, SojungKnight, Robert D.Lu, EmilyWang, RuipengAl Malki, Monzr M.
- [10] Efficacy and risk of donor-derived CAR-T treatment of relapsed B-cell acute lymphoblastic leukemia after hematopoietic stem cell transplantationCYTOTHERAPY, 2024, 26 (11) : 1301 - 1307Deng, LeiYu, XiaolinSong, XiaochengGuan, RuiLi, WenjunHou, YixiShao, YanZhao, YuerongWang, JingLiu, YueXiao, QianqianXin, BoZhou, Fang